NCT03959384

Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age

Terminated Phase 3 Last updated 15 April 2021

What this trial tests

Phase 3 trial testing Curosurf 80Mg/Ml Intratracheal Suspension in Bronchiolitis, Viral in 9 participants. Terminated before completion.

Timeline

9 January 2019

Primary endpoint
9 April 2021

9 April 2021

Quick facts

Lead sponsor	Azienda Ospedaliera Universitaria Integrata Verona
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	9
Start date	9 January 2019
Primary completion	9 April 2021
Estimated completion	9 April 2021
Sites	1 location across Italy

Drugs / interventions tested

• Curosurf 80Mg/Ml Intratracheal Suspension — full drug profile →
• Ambient Air — full drug profile →

Conditions studied

• Bronchiolitis, Viral — all drugs for Bronchiolitis, Viral →

Sponsor

Azienda Ospedaliera Universitaria Integrata Verona — full company profile →

Who can join

Adults 40 Weeks to 12 Months, any sex, with Bronchiolitis, Viral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background. Viral bronchiolitis is a common cause of hospitalization for acute respiratory insufficiency in young infants. Despite several RCT have tested the effectiveness of various agents, currently there is no proven specific therapy for bronchiolitis, treatment remaining mostly supportive. Based on available studies, exogenous surfactant replacement in bronchiolitis is likely to have a promising safety and efficacy profile. Primary objective. To evaluate whether Curosurf treatment is effective compared to placebo (air) in reducing the duration of invasive mechanical ventilation in the first 14 days of hospitalization, in infants less than 12 months suffering from acute hypoxemic bronchiolitis. Methods. a multicenter, double-blind, placebo-controlled, randomized trial. 19 Italian PICUs will enroll children less than12 months with hypoxemic acute bronchiolitis, with need for invasive mechanical ventilation. Once the patient has been recruited, randomization should occur as quickly as possible. The first dose of Curosurf or placebo should be administered within 60 minutes of randomization. The treatment may be repeated once, not before 12 hours and not later than 24 hours after the initial dose. The assignment of the type of treatment will be communicated by the Coordinator center to the researcher attending the patient's bed. The same medical researcher will then take care of administering the assigned treatment, masking the procedure with appropriate precautions, for example with screens or closing the patient's room whenever possible. The preparation and administration of treatment, medication or placebo, can be done by a nurse who must not disclose the assigned treatment and will not be involved in the patient's care until the conclusion of the study. Patient evaluation will be carried out by other physicians and/or nurses who will not be aware of the assigned treatment. Regardless the received treatment, all patients will be assisted according to standard practice of the Unit. For the purposes of the study, several parameters will be collected 15 minutes before, and 2, 6, 12, 24, 36, 48 hours after administration of the drug: oxygenation indexes such as OI, OSI, PaO2 and SatO2; Invasive ventilation parameters, i.e. current volume, positive end expiratory pressure, peak pressure, respiratory rate, FiO2 and mean airway pressure; and ventilation indexes such as PaCO2 and End Tidal CO2. If it is necessary to repeat the treatment, the above parameters will be re-collected with the same timepoints. During the study all the AE/ADR will be recorded.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Efficacy and safety of exogenous surfactant therapy in patients under 12 months of age invasively ventilated for severe bronchiolitis (SURFABRON): protocol for a multicentre, randomised, double-blind, controlled, non-profit trial.
   Biban P, Conti G, Wolfler AM, Carlassara S, et al · · 2020 · cited 3× · PMID 33077567 · DOI 10.1136/bmjopen-2020-038780